Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Vitamin D levels in midlife tied to lower dementia risk marker

Having higher levels of vitamin D in the blood in middle age is associated with lower levels of tau protein in the brain, which is a sign of dementia, years later, according to a study published April 1, 2026, in Neurology® Open Access, an official journal of

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Having higher levels of vitamin D in the blood in middle age is associated with lower levels of tau protein in the brain, which is a sign of dementia, years later, according to a study published April 1, 2026, in Neurology® Open Access, an official journal of the American Academy of Neurology. The study does not prove that vitamin D levels lower the level of tau and the risk of dementia; it only shows an association.

These results suggests that higher vitamin D levels in midlife may offer protection against developing these tau deposits in the brain and that low vitamin D levels could potentially be a risk factor that could be modified and treated to reduce the risk of dementia. Of course, these results need to be further tested with additional studies." Martin David Mulligan, MB BCh BAO, study author, University of Galway, Ireland

The study involved 793 people with an average age of 39 who did not have dementia. All of the participants had the level of vitamin D in their blood measured at the start of the study. They had brain scans an average of 16 years later that measured levels of tau and amyloid beta proteins in the brain, which are both biomarkers for Alzheimer's disease. A high level of vitamin D was defined as greater than 30 nanograms per milliliter (ng/mL) and a low level was less than that number.

A total of 34% of participants had low levels of vitamin D and 5% were taking vitamin D supplements.

The researchers took into account other factors that could affect tau levels, such as age, sex and symptoms of depression.

Higher vitamin D levels were associated with lower levels of the Alzheimer's biomarker tau protein years later.

There was no relationship between vitamin D levels and the amount of amyloid beta protein in the brain.

"These results are promising, as they suggest an association between higher Vitamin D levels in early middle-age and lower tau burden on average 16 years later," Mulligan said. "Mid-life is a time where risk factor modification can have a greater impact."

A limitation of the study is that the blood level of vitamin D was measured only once.

The study was supported by the National Institute on Aging, National Institute of Neurological Disorders and Stroke, Irish Research Council and Health Research Board of Ireland.

Mulligan, M. D., et al. (2026). Association of Circulating Vitamin D in Midlife With Increased Tau-PET Burden in Dementia-Free Adults. Neurology Open Access. DOI: 10.1212/wn9.0000000000000057. https://www.neurology.org/doi/10.1212/WN9.0000000000000057

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01With graph neural networks, foundation models, and diffusion models transforming the field, what can we predict reliably today that was difficult a decade ago and are there still any blind spots?

One major example is protein structure. Methods such as AlphaFold and Boltz-2 have transformed how we generate 3D structural data. Accurate protein structure prediction has been a decades-old challenge, and while there is still work to do on underrepresented protein classes, these models have opened an extraordinary pathway. We have also seen progress in multi-output models. Just over a decade ago (circa 2013), toxicology and property prediction models often focused on one endpoint at a time. Now, multi-output models, especially from methods such as graph neural networks (GNNs) and other deep learning methods, can predict multiple endpoints simultaneously. This allows for transfer learning between related properties. That creates opportunities across ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction and toxicology. Another exciting area is machine learning potentials. Molecular simulations traditionally rely on fixed mathematical functions to describe molecular interactions, but neural potentials can now replace or augment those functions. They can, in many cases, provide highly accurate simulations and structures at lower computational cost than quantum chemistry. However, its not just down to model architectures. The biggest blind spot behind all of these advances remains careful data curation, annotation, and collection. Open databases for example ChEMBL, PubChem and Chemspider together with data initiatives such as OpenADEMT and OpenBind to name but a few are making notable progress here. We still see some data for example on formulation chemistry often receiving less attention. Its is not just about data scale, but quality that is critical here to. Accessible high quality data sets are the fuel of AI methods. Architecture matters, but high-quality, accessible and abundant data is also absolutely critical.

Source: www.news-medical.net ↗
02How will this discovery change cancer science?

This is a win for the field. Until now, we have been focused on immune therapies that might make tumors more vulnerable to the body's immune system, and on finding new chemotherapy combinations that kill cancer cells. This new treatment has given us a new focus, and I think it will spur a lot of scientific discovery over the next few years. There have only been a handful of KRAS researchers and their relevance to therapy was always questioned. That is about to change. The most important next step for the field is to better understand the biology of cancer. We know that many pancreatic tumors will eventually become resistant to daraxonrasib, and we need to understand how this happens. We also need to identify additional genetic pathways and treatments that can target them. That's how we will turn pancreas cancer from a deadly, deadly cancer into something we can manage-and one day, even cure.

Source: www.news-medical.net ↗
03What impact do you think the use of AI in drug discovery could ultimately have for patients?

One of the first ways in which this would be really felt by patients is through the repurposing of existing drugs for new diseases. Clearly, even though one could improve the process in a number of ways in terms of speeding up medicinal chemistry programs and potentially speeding up the amount of things such as toxicity trials etc., that is still going to take time. However, if we can take existing drugs, perhaps drugs which have gone off patent or are currently being marketed for another indication, and repurpose them in areas where there are high unmet medical needs, those drugs could go into that new indication in phase 2 in patients and you would know very quickly whether the drug worked or not. Then the route to market or the route to being able to make the drug more broadly available to patients would be much more rapid because you don't have to go through all those earlier stages of toxicity, testing, phase 1 testing, volunteers and so on.

Source: www.news-medical.net ↗
04From Spirulina to Seaweed: How are different types of algae integral to human diets?

Algae are photosynthetic aquatic creatures that grow through the consumption of nutrients, light, and carbon dioxide. They are a diverse group of creatures that include tiny single-celled algae and enormous kelp, as well as seaweed 1. Numerous prokaryotic and eukaryotic algae species are desirable food sources for humans due to their inherent qualities 2,3. Human intake of macroalgae such as seaweed and microalgae like phytoplankton dates back many years. Multicellular macroscopic aquatic plants, or macroalgae, are classified into three taxa: Phaeophyceae, or brown algae, Rhodophyta or red algae, and Chlorophyta or green algae. Microalgae, the unicellular counterpart of macroalgae, are categorized in a broader framework that includes prokaryotic cyanobacteria (blue-green algae), Euglenophyta, and Chlorophyta, which are genetically distinct from one another. The ancient populations of Chad and the Aztec culture were already familiar with the cyanobacteria spirulina, which is currently advertised as a superfood in the West 4. In Burma, Vietnam, and India, other cyanobacteria/microalgae, like Spirogyra and Oedogonium, were eaten as food or as a supplement 4. Seaweed is a staple of daily meals in many Asian and Pacific civilizations, including Korea, Japan, and Indonesia, as well as Hawaii and New Zealand 5.

Source: www.news-medical.net ↗
05What is carb cycling?

Carb cycling is an attempt to fine-tune your carbohydrate consumption to alter many aspects of your metabolism. Your plan will include the same protein intake each day but vary carbohydrates according to your activity. Your carb cycling plan may have three low or zero carb days, two moderate carb days, and two high carb days. Meeting your calorie requirements will require including more fats on low-carb days. Carb cycling needs much more planning than a usual calorie-controlled diet. One way is to match your carb cycling to your physical activity. If you go to the gym thrice a week, you could have carbs on those days. The carbs provide energy for your workout, prevent fatigue, and avoid the muscle loss sometimes seen with dieting. The days when you eat little to no carbs force your body to generate energy from other sources, like proteins and fats. But the days when you eat more carbohydrates might reverse this change. You must only eat a high-carb diet on the days you have a heavy workout, which uses up the calories.

Source: www.medicinenet.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →